The global digital pathology market is projected to be valued at USD 383.9 Million in 2016 and is expected to grow at a CAGR of 12.3% from 2017 to reach to USD 756.1 Million by 2022.
Key Growth Drivers :
1 Increasing Adoption of Digital Pathology to Enhance Lab Efficiency
2 Rising Prevalence of Cancer
3 Growing Applications of Digital Pathology in Drug Development and Companion Diagnostics
4 Ease of Consultation Enabled By Digital Pathology
5 Increasing Initiatives By Governments and Industry Players
1 Increasing Adoption of Digital Pathology to Enhance Lab Efficiency
2 Rising Prevalence of Cancer
3 Growing Applications of Digital Pathology in Drug Development and Companion Diagnostics
4 Ease of Consultation Enabled By Digital Pathology
5 Increasing Initiatives By Governments and Industry Players
Geographic Snapshot :
In 2017, North America is expected to account for the largest share of the digital pathology market, followed by Europe. The large share of the North American region can be attributed to factors such as increasing initiatives by industry players and governments in diagnostics and the rising prevalence of chronic diseases.
Market Key Players:
The prominent players in the global digital pathology market are Leica Biosystems (Germany), Ventana Medical Systems (US), Hamamatsu Photonics (Japan), 3DHISTECH (Hungary), Philips (Netherlands), Apollo Enterprise Imaging (US), XIFIN (US), Visiopharm (Denmark), Corista (US), Huron Digital Pathology (Canada), Objective Pathology Services (Canada), and Indica Labs (US).
Comments
Post a Comment